Insights | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Article | August 12, 2015

Process Patents Are Vital In Biotech — Why Not Extend Them?

Blog | June 12, 2015

Hatch-Waxman Actions: Who Do You (Can You) Sue?

Article | June 02, 2015

Commil V. Cisco — Who Really Won?

Article | May 19, 2015

Personal Jurisdiction in Hatch-Waxman Actions In View of Daimler

Article | April 06, 2015

Post-Approval Conduct and the Hatch-Waxman Safe Harbor

Webinar | March 18, 2015

Recent Developments Impacting Hatch-Waxman Litigation

Article | January 08, 2015

Inter Partes Review by Hatch-Waxman Competitors Will Likely Increase Because of the Effect of IPR Decisions on the 30-Month Stay

Article | October 24, 2014

Government Heeds Fish's Admonition

Blog | September 19, 2014

Drug Labels Can Provide The "Specific Intent" Required For Inducement Of Infringement

Blog | August 12, 2014

IPR's and the Hatch-Waxman 30-Month Stay of FDA Approval

Article | February 14, 2014

In Vivo Conversion As Inducement To Infringe